Conditions: Myelodysplastic Syndrome
Keywords: deferasirox MDS RNA expression predictive biomarker
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1
Healthy volunteers: no

Brief summary:
Several previous studies (clinical and non-clinical) hypothesize that treatment with deferasirox causes a hematological improvement in transfused patients with low and intermediate-1 risk myelodysplastic syndrome. The purpose of this study was to assess the presence of genetic biomarkers predictive for hematologic response by the use of gene expression profiling of bone marrow aspirates obtained from MDS patients with or without hematological response.

Detailed description:
This trial was terminated due to low enrollment.

Arms:
arm 1: All patients are already on commercial deferasirox before entering the study.

Interventions: intervention 1: Bone marrow aspirate intervention 2: Deferasirox
Intervention descriptions: intervention 1: Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups intervention 2: Patients are already on commercial deferasirox before entering the study.

Protocol document: